Mesoblast Limited

Contributing Author

Recent Articles by Mesoblast Limited

Jun-30	Mesoblast and FDA Align on Key Items for Revascor Biologic License Application in Ischemic Heart Failure MESO +11.29% GlobeNewswire
Jun-11	Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor in Ischemic Heart Failure and Label Extension for Ryoncil in Adults With GvHD MESO GlobeNewswire
May-14	FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil MESO GlobeNewswire